Shares of Edap Tms SA (NASDAQ:EDAP) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus target price of $6.50 for the company and are forecasting that the company will post $0.01 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Edap Tms an industry rank of 160 out of 265 based on the ratings given to its competitors.
Several brokerages recently issued reports on EDAP. Zacks Investment Research raised Edap Tms from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research note on Thursday. ValuEngine downgraded Edap Tms from a “hold” rating to a “sell” rating in a research note on Sunday, December 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $6.50 price objective on shares of Edap Tms in a research note on Wednesday, November 22nd.
Shares of Edap Tms (NASDAQ:EDAP) traded down $0.02 during trading on Wednesday, reaching $2.70. The company had a trading volume of 73,809 shares, compared to its average volume of 53,969. The stock has a market cap of $78.87, a P/E ratio of -33.75 and a beta of 1.02. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.35 and a current ratio of 2.96. Edap Tms has a 1 year low of $2.25 and a 1 year high of $3.85.
Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings data on Wednesday, November 15th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). The firm had revenue of $8.44 million during the quarter, compared to the consensus estimate of $11.05 million. Edap Tms had a positive return on equity of 7.85% and a negative net margin of 5.36%. The firm’s quarterly revenue was down 5.6% on a year-over-year basis. research analysts forecast that Edap Tms will post -0.01 earnings per share for the current year.
WARNING: “Zacks: Analysts Set $6.50 Target Price for Edap Tms SA (EDAP)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3147939/zacks-analysts-set-6-50-target-price-for-edap-tms-sa-edap.html.
Edap Tms Company Profile
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.